PE-22-28 for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

PE-22-28 for Health & Longevity

Created on 10/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

PE-22-28 is a laboratory-made peptide, sold online and by private clinics for mood and brain function. It is designed to block one channel that keeps nerve cells quiet. Every claimed benefit — faster mood-related change, new brain cells, stroke recovery, protection of insulin-producing cells — rests on mice, rats and cultured cells, almost all from the patent-holding laboratory. No benefit or risk has been measured in people. Supply is unregulated. (Full Review)

Protocol

Published animal regimen
3.0 µg/kg daily for 4 days
Mice, intraperitoneal injection (into the abdominal cavity), or 1 mg/kg by gavage (tube into the stomach); the only validated dose
Amounts reported in private practice
2–10 mg single doses
No trial supports these figures; not convertible from the rodent dose
Competing route approaches
Intranasal spray or subcutaneous injection
Oral dosing worked in mice only at a much higher dose; none compared in people
Time to effect
Antidepressant-like behaviour
Single dose; consolidated over 4 days
Rodents only; no human timeline exists
New hippocampal cells
4 days of treatment
Mouse hippocampus; cell and animal work only

Benefits

Contraindications
  • Epilepsy or a prior unprovoked seizure (no numeric threshold given)
  • Abnormally slow heart rate, sinus-node disease or a cardiac conduction disorder
  • Known KCNK2 variant carriers, and unexplained ventricular arrhythmia
  • Use of insulin or insulin-releasing medicines, and recurrent low blood sugar
  • Glaucoma or raised intraocular pressure
  • Autoimmune disease of the central nervous system, such as multiple sclerosis
  • Current or past cancer
  • Pregnancy or breastfeeding, and anyone under 18
  • Recovery period after a stroke
    •
Key Interactions
  • Selective serotonin reuptake inhibitors (fluoxetine, sertraline; caution, theoretical)
  • Polyunsaturated fatty acid supplements (fish oil, flaxseed oil; monitor, theoretical)
  • Quercetin and other plant flavonoid supplements (monitor, theoretical)
  • Volatile anaesthetics (sevoflurane, isoflurane; caution, theoretical)
  • Glucose-lowering supplements (berberine, chromium picolinate; monitor, theoretical)
  • Riluzole (monitor, theoretical)
  • Antiseizure medicines (levetiracetam, lamotrigine; caution, theoretical)
  • Over-the-counter stimulants (caffeine tablets, theophylline preparations; caution, theoretical)
  • Intermittent fasting, ketogenic eating, prolonged endurance sessions (monitor, theoretical)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Lower Seizure Threshold; Heightened Pain Sensitivity; Worse Outcome From Brain Ischaemia; Slow Heart Rate and Pauses; Worse Cardiac Remodelling; Atrial Rhythm Disturbance; Raised Pulmonary Blood-Vessel Tone; Low Blood Sugar; Easier Immune-Cell Entry Into the Brain; Raised Pressure Inside the Eye; More Fat Accumulation and Poorer Glucose Tolerance; Unchecked Cell Growth; Harm From Unverified Product Identity, Purity or Sterility; Unknown Immune Reaction to the Peptide
    •

Monitoring

Marker Target Why
Fasting plasma glucose 70–99 mg/dL Safety check: a fall below range stops or reduces use
Fasting insulin 2.6–24.9 µIU/mL Safety check: a rise above range with falling glucose signals the insulin-release effect
Resting 12-lead electrocardiogram No established target; tracked against the individual's own pre-exposure recording Safety check: a new slow rate, pause or conduction change stops use
Intraocular pressure 10–21 mmHg Safety check: a rise above range stops use

Cadence: Baseline, at four weeks, then every three to six months during exposure; fasting glucose and insulin sooner if low blood sugar symptoms appear. Intervals reflect common practice for an unstudied compound, not a trial.

Qualitative Assessment

  • Mood, using the same standard depression rating scale at the same time of week
  • Sleep onset latency and night-time waking
  • Energy and motivation during the first two weeks
  • Cognitive clarity and short-term memory
  • Episodes of sweating, tremor, hunger or confusion between meals
  • New visual symptoms, eye ache or haloes around lights
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.